Cargando…

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Donata, Corleis, Björn, Rauch, Susanne, Roth, Nicole, Mühe, Janine, Halwe, Nico Joel, Ulrich, Lorenz, Fricke, Charlie, Schön, Jacob, Kraft, Anna, Breithaupt, Angele, Wernike, Kerstin, Michelitsch, Anna, Sick, Franziska, Wylezich, Claudia, Hoffmann, Bernd, Thran, Moritz, Thess, Andreas, Mueller, Stefan O., Mettenleiter, Thomas C., Petsch, Benjamin, Dorhoi, Anca, Beer, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245475/ https://www.ncbi.nlm.nih.gov/pubmed/34193869 http://dx.doi.org/10.1038/s41467-021-24339-7

Ejemplares similares

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021)

A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
por: Lenart, Klara, et al.
Publicado: (2022)

Experimental SARS-CoV-2 Infection of Bank Voles
por: Ulrich, Lorenz, et al.
Publicado: (2021)

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
por: Wolz, Olaf-Oliver, et al.
Publicado: (2022)

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses
por: Roth, Nicole, et al.
Publicado: (2022)

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

Occurrence of Antibodies against SARS-CoV-2 in the Domestic Cat Population of Germany
por: Michelitsch, Anna, et al.
Publicado: (2020)

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
por: Corleis, Björn, et al.
Publicado: (2023)

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
por: Kremsner, Peter G, et al.
Publicado: (2022)

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

The Second Wave of SARS-CoV-2 Circulation—Antibody Detection in the Domestic Cat Population in Germany
por: Michelitsch, Anna, et al.
Publicado: (2021)

Susceptibility of Raccoon Dogs for Experimental SARS-CoV-2 Infection
por: Freuling, Conrad M., et al.
Publicado: (2020)

SARS-CoV-2 in animals: From potential hosts to animal models
por: Michelitsch, Anna, et al.
Publicado: (2021)

Experimental Infection of Cattle with SARS-CoV-2
por: Ulrich, Lorenz, et al.
Publicado: (2020)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

SARS-CoV-2 Infection and Clinical Signs in Cats and Dogs from Confirmed Positive Households in Germany
por: Michelitsch, Anna, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice
por: Zhang, Cheng, et al.
Publicado: (2022)

Multi‐species ELISA for the detection of antibodies against SARS‐CoV‐2 in animals
por: Wernike, Kerstin, et al.
Publicado: (2020)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Saving Resources: SARS-CoV-2 Diagnostics by Real-Time RT-PCR Using Reduced Reaction Volumes
por: Bock, Sabine, et al.
Publicado: (2021)

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
por: Kim, Yeong Jun, et al.
Publicado: (2021)

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
por: Mwenda, Mulenga, et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
por: Feder, Kenneth A., et al.
Publicado: (2021)

Early detection of community acquired of SARS-CoV-2 lineage B.1.351 in Hong Kong
por: Tsang, Alan K.L., et al.
Publicado: (2021)

Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice
por: Yasui, Fumihiko, et al.
Publicado: (2022)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
por: Dayan, Gustavo H., et al.
Publicado: (2023)

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models
por: Roth, Nicole, et al.
Publicado: (2023)

Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India
por: Yadav, Pragya D., et al.
Publicado: (2021)

Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant
por: Yinda, Claude Kwe, et al.
Publicado: (2021)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
por: Novazzi, Federica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ifvjd8lep1vo19mu4u0ratdri